Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101
2012
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Estimating the mean and variance from the median, range, and the size of a sample
2005 Standout
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy
2005
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
2010 Standout
Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
2005
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Breast cancer
2019 Standout
Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced Breast Cancer
2006
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
2005
Targeted Therapy in Breast Cancer
2004
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
2007 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
2004
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids
2004
The DNA-damage response in human biology and disease
2009 StandoutNature
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
2013 Standout
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
2002
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Development of Herceptin resistance in breast cancer cells
2003
Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response
2014
EGF–ERBB signalling: towards the systems level
2006 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
2014 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Targeting multidrug resistance in cancer
2006 Standout
Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer
2010
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
2009 Standout
Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience
2002
Magnetic nanoparticles in MR imaging and drug delivery
2008 Standout
Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™)
2009
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Tumor delivery of macromolecular drugs based on the EPR effect
2010 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Classification of anticancer drugs—a new system based on therapeutic targets
2003
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Erythropoietin for patients with malignant disease
2004
FcRn: the neonatal Fc receptor comes of age
2007 Standout
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Anemia of Chronic Disease
2005 Standout
Breast cancer metastasis: markers and models
2005 Standout
Emerging targeted agents in metastatic breast cancer
2013
Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer
2001
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
2009 Standout
Therapeutic Nanoparticles for Drug Delivery in Cancer
2008 Standout
Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
2005
Targeted Therapies for Cancer 2004
2004
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
2002 Standout
Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
2001
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
2006
Liposomal Formulations in Clinical Use: An Updated Review
2017 Standout
Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems
2018 Standout
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Overview of monoclonal antibodies in cancer therapy: present and promise
2005
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
2003
Mitogen-Activated Protein Kinase Activation in UV-Induced Signal Transduction
2003
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
Molecular targets of dietary agents for prevention and therapy of cancer
2006 Standout
Analysis of nanoparticle delivery to tumours
2016 Standout
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer
2004
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
2009
Primary Systemic Therapy of Breast Cancer
2006
Works of EP Winer being referenced
Trastuzumab/chemotherapy combinations in metastatic breast cancer
2002
P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial.
2011
Abstract S6-3: Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 — A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy
2010
Liposomal anthracyclines for breast cancer
2001
Cardiac safety and efficacy of TLC D99 (D99) and trastuzumab in patients with advanced breast cancer
2001
A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease
2004
796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-SCF support
1997
Oral 5-FU analogues in the treatment of breast cancer.
1998
Preoperative trastuzumab (T) and paclitaxel (P) for HER2-overexpressing (HER2+) stage breast cancer
2001
397 Preoperative trastuzumab and vinorelbine (HN) is a well-tolerated, active regimen for Her2 3+/FISH+stage II/III breast cancer
2003
Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.
1996